Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

ClinicalTrials.gov ID: NCT01361607

Public ClinicalTrials.gov record NCT01361607. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This 9-week study aimed to determine the efficacy, safety, and tolerability of nabiximols (Sativex®) as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in participants with advanced cancer. Eligible participants were not required to stop any of their current treatments or medications.

Study identification

NCT ID: NCT01361607
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Jazz Pharmaceuticals; Industry
Enrollment: 399 participants

Conditions and interventions

Conditions

Interventions

Nabiximols Drug
Placebo (GA-0034) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 26, 2011
Primary completion: Nov 23, 2014
Completion: Nov 23, 2014
Last update posted: Apr 11, 2023

2011 – 2014

United States locations

U.S. sites: 20
U.S. states: 11
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Glendale	California	91204	—
Not listed	Santa Rosa	California	95403	—
Not listed	Clearwater	Florida	33756	—
Not listed	Holiday	Florida	34691	—
Not listed	Miami	Florida	33136	—
Not listed	Stuart	Florida	34994	—
Not listed	Marietta	Georgia	30060	—
Not listed	Newnan	Georgia	30265	—
Not listed	Stockbridge	Georgia	30281	—
Not listed	Gurnee	Illinois	60031	—
Not listed	Mount Vernon	Illinois	62864	—
Not listed	Ashland	Kentucky	41101	—
Not listed	Bossier City	Louisiana	71111	—
Not listed	Shreveport	Louisiana	71105	—
Not listed	Missoula	Montana	59802	—
Not listed	Berlin	New Jersey	08009	—
Not listed	New York	New York	10003	—
Not listed	New York	New York	10010-4086	—
Not listed	Cleveland	Ohio	44119	—
Not listed	Lacey	Washington	98503-1010	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01361607, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 11, 2023 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01361607 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →